Navigation Links
New Positive Phase III Study for NER1006 - The First 1 Litre PEG-Based Bowel Preparation
Date:5/24/2016

LONDON, May 24, 2016 /PRNewswire/ --

 

  • Study met both primary endpoints demonstrating non-inferiority in overall bowel cleansing and superiority in 'Excellent plus Good' cleansing of the ascending colon 

     (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )

Norgine B.V. today announced new positive data from the phase III MORA study for NER1006 (1 litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ascorbate. The study met both primary endpoints showing that when administered as either a 2-day overnight or 1-day morning split-dosing regimen, and compared to 2L PEG, NER1006 was:

  • Non-inferior in achieving overall bowel cleansing
  • Non-inferior and superior in achieving 'Excellent plus Good' cleansing of the ascending colon

In addition, the study showed that as a 2-day overnight or 1-day morning split-dosing regimen, NER1006 was non-inferior in detecting adenomas and polyps in the ascending and overall colon and as a 2-day overnight split-dosing regimen, it demonstrated a superior polyp detection rate in the ascending colon.

The overall tolerability and safety profile of NER1006 was comparable to that of 2L PEG. Treatment related adverse events were mild or moderate in severity and reflected the expected safety profile of the respective treatments.

The threshold for statistical significance in this study was P<0.025 and a 10% margin was used to demonstrate non-inferiority vs. 2L PEG. [1]

Peter Martin, Norgine's Chief Operating Officer, said: "The new positive phase III MORA results for NER1006 are promising because we know that the quality of a bowel preparation is an important factor for a successful colonoscopy and detecting polyps and tumours. These data reinforce Norgine's leadership in colonoscopy to provide patients with innovative treatments."

NER1006 is not yet approved for use. Norgine intends to submit NER1006 for approval in the US and EU.

The data was presented at Digestive Disease Week on 24 May 2016, 09:30-16:30.


To view the full press release go to http://www.norgine.com

References 

1. Raf Bisschops, Jonathan Manning, Lucy Clayton, Richard Ng Kwet Shing, Marco A. Alvarez-Gonzalez (2016): Efficacy and Safety of the Novel 1L PEG and Ascorbate Bowel Preparation NER1006 Versus Standard 2L PEG With Ascorbate in Overnight or Morning Split-Dosing Administration: Results from the Phase 3 Study MORA. Gastroenterology, Vol. 150, Issue 4, S1269-S1270. Abstract Tu2084. 

 

Media Contacts:
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @norgine
 



'/>"/>
SOURCE Norgine B.V.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. PharmaMar Reports Positive Results from the Phase I Study of plitidepsin in Combination with bortezomib and dexamethasone in Patients with Multiple Myeloma at the 2016 ASCO Annual Meeting
2. Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study
3. Breast Pumps Outlook Remain Positive, Sleek, Smart to Dominate the Market: Future Market Insights (FMI)
4. Celsion Corporation Announces Positive Data from the First Cohort of Patients in the OVATION Study
5. Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer
6. NICE Provides Positive Guidance on electroCores gammaCore Treatment for the Prevention and Acute Treatment of Migraine and Cluster Headache
7. Sylentis Reports Positive Phase II Results With SYL1001 in Treating Ocular Pain Related to Dry Eye Syndrome
8. Alexza Pharmaceuticals Receives Positive Nasdaq Listing Determination
9. ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
10. 2016 HIMSS Connected Health Survey Suggests Positive Future for Connected Health Technologies in U.S. Hospitals
11. scPharmaceuticals Announces Positive Results from Pivotal Trial of Second Program - Subcutaneous Ceftriaxone for Treatment of Bacterial Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... its Board of Directors has approved the payment of a ... 2017. The cash dividend ... October 27, 2017 to stockholders of record as of the ... dividends are subject to approval of the Board of Directors ...
(Date:8/7/2017)... DUBLIN , Aug. 7, 2017  Endo International ... has reached agreements to resolve virtually all known U.S. ... in discussions to resolve the known remaining U.S. claims ... installment payments beginning in the fourth quarter of 2017 ... part of its second quarter 2017 results, the Company ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Nurses at Apple ... picturesque Babcock Cove, recently received training and certification in Closed Pulse Irrigation™ ... a prestigious five-star rating from the Centers for Medicare and Medicaid Services, to have ...
(Date:8/22/2017)... ... ... “To Walk Away”: a captivating and romantic sequel to the romantic story ... is the creation of published author, Larry R. Sherman, a retired chemistry professor from ... religion, as well as four novels. , Though the book opens in 1947, ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Without Love’s ... and neglect, and the struggles faced while hoping for a better life. “Without ... author, Judy Von Bernewitz, who spent 13 years working with deprived/neglected adolescents and ...
(Date:8/22/2017)... , ... August 22, 2017 , ... “Glimpses Of Light”: ... of the world. “Glimpses Of Light” is the creation of published author, J.M. Shepherd, ... in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is one ...
(Date:8/22/2017)... ... 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5-star rating to Energy NADH, ... stress of modern life continually makes more demands on time and energy, people are ... trap people in vicious high/low cycles and can also cause long term health issues. ...
Breaking Medicine News(10 mins):